Copyright © Inderes 2011 - present. All rights reserved.
  • Senaste
  • Börs
    • Aktiejämförelse
    • Börskalender
    • Utdelningskalender
    • Aktieanalys
    • Artiklar
  • InderesTV
  • Portfölj
  • Forum
  • Q&A
  • Om oss
    • Bolag under bevakning
    • Teamet
Pressmeddelande

Redeye: Moberg Pharma Q4’2024 - All eyes on the European market

Moberg Pharma

Redeye views the Q4 report as uneventful in many respects, as most of the events were communicated during the quarter. The plan to launch in the EU is the same, and the path to the US is not closed, but it will take time, and the conditions have to be right. We add Norway and deduct S. Korea from our estimates. We must get further insight into how the EU market strategy will pan out during 2025 to make more significant changes. The current changes to our estimates increase our Base case to SEK 11 (9.5) per share. Following this report, we are changing the head analyst.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments


Moberg Pharma Q4’2024 - All eyes on the European market

Följ oss på våra kanaler i social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Ta kontakt
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • Om oss
  • Teamet
  • Jobba hos oss
  • Inderes som en investering
  • Tjänster för börsbolag
Vår plattform
  • FAQ
  • Servicevillkor
  • Integritetspolicy
  • Disclaimer
Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.